Virginia's Pharma Hub Gets $16M Federal Boost to End Drug Shortages

RICHMOND, VA – July 21, 2026 – Virginia’s rapidly expanding pharmaceutical sector received another major vote of confidence this week, securing a $15.97 million federal investment to build a fully domestic supply chain for essential medicines. The U.S. Economic Development Administration (EDA) grant will fund the End-to-End (E2E) Commercialization Project, an initiative aimed at severing the nation's reliance on fragile global networks and mitigating persistent drug shortages.

The project is spearheaded by the Alliance for Building Better Medicine, a 55-partner coalition leading Virginia’s Advanced Pharmaceutical Manufacturing (APM) Tech Hub. Nonprofit drug manufacturer Civica, Inc. will lead the effort, with critical support from public benefit corporation Phlow Corp. and AI-driven chemical sourcing firm Occam Systems.

A Strategic Response to National Vulnerabilities

For decades, the United States has offshored the production of its most critical medicines, leaving more than 130 million Americans dependent on increasingly complex and vulnerable global manufacturing networks. This strategic weakness has resulted in chronic shortages of life-saving drugs, a problem exacerbated by geopolitical tensions and public health crises. The new federal funding, part of the EDA’s Tech Hubs Program created under the CHIPS and Science Act, represents a significant strategic shift toward reshoring this critical industry.

"Virginia is an emerging leader in advanced pharmaceutical manufacturing, and we are committed to uniting industry, researchers, educators, workforce partners, and public leaders around a shared goal: ensuring medicines are reliably developed and manufactured in the United States," said Governor Abigail Spanberger. "This transformational investment from the EDA reflects a confidence in Virginia's future that will help us create job opportunities for Virginians, encourage innovation, and strengthen our nation's pharmaceutical manufacturing ecosystem."

The project aims to create a secure, entirely U.S.-based commercialization pathway, from the earliest chemical ingredients to the finished sterile medicines delivered to hospitals and patients. It is a direct response to a national security imperative to guarantee access to essential therapies.

From Lab to Life-Saving: Tackling Critical Drug Shortages

The initiative will initially focus on four essential sterile injectable medicines used daily in emergency rooms, operating theaters, and intensive care units: ketamine, midazolam, norepinephrine, and succinylcholine. All have been subject to debilitating shortages that directly impact patient care.

Ketamine, for instance, has been on the FDA's shortage list since 2018 due to manufacturing disruptions and increased demand. Midazolam, a critical ICU sedative, faced severe scarcity during the COVID-19 pandemic and continues to be on backorder from multiple manufacturers. Succinylcholine, a first-line drug for emergency intubation, has also seen its supply constrained by manufacturer discontinuations and production delays. While norepinephrine is not currently in a widespread shortage, a 2011 scarcity was associated with a nearly 4% increase in mortality for patients with septic shock, highlighting the life-and-death stakes of a stable supply chain.

The E2E project creates a seamless, integrated domestic pipeline to combat these issues. Occam Systems will use its generative AI platform to source and develop key starting materials (KSMs) domestically. Phlow Corp., which specializes in advanced continuous manufacturing, will then convert those materials into active pharmaceutical ingredients (APIs). Finally, Civica will manage the finished dose formulation, navigate FDA approval, and handle commercial manufacturing and distribution to its network of over 1,500 hospitals.

"This initiative aligns with our mission to ensure that essential medicines remain available, affordable, and reliably supplied for the hospitals, healthcare providers, and patients who depend on them every day," said Ned McCoy, CEO of Civica. "That mission is as important today as it was when Civica was founded, and it continues to drive everything we do."

Virginia's Biotech Boom: A Decade of Deliberate Growth

The $15.97 million grant is not a starting pistol but rather a booster rocket for an engine that has been meticulously built over the last decade. The award builds on more than $1.7 billion in prior federal, state, and private investment that laid the groundwork for Virginia's APM Tech Hub. The momentum began with the founding of the Medicines for All Institute at Virginia Commonwealth University in 2017 and accelerated with the creation of Phlow Corp. and the Alliance for Building Better Medicine in 2020.

Key milestones include a $52.9 million EDA Build Back Better Regional Challenge grant in 2022 and the formal designation of the Richmond-Petersburg region as a national APM Tech Hub in 2023. This sustained, collaborative effort has created a fertile ground for massive private investment. In 2025 alone, Virginia announced over $13 billion in advanced pharmaceutical manufacturing commitments from industry giants AstraZeneca, Eli Lilly, and Merck.

"This milestone reflects years of partnership, persistence, and shared commitment at the federal, state, regional, and local levels," said Joy Polefrone, Ph.D., Regional Innovation Officer for the APM Tech Hub. "We are equally grateful to the Alliance's founding members and our 55 partners who chose collaboration over competition to build something larger than any one organization could accomplish alone."

Building the Workforce for a Domestic Pharma Revolution

This influx of capital and technology is fueling a parallel revolution in workforce development. The massive investments from AstraZeneca, Eli Lilly, and Merck are projected to create over 1,750 high-paying jobs, a nearly 60% increase in the state's direct pharmaceutical manufacturing employment. These roles, with some salaries projected to average $125,000, demand a new generation of skilled technicians and scientists.

To meet this demand, the state and its partners have launched a comprehensive workforce pipeline. The cornerstone is the Virginia Center for Advanced Pharmaceutical Manufacturing (VCAPM), an industry-led training network backed by a $120 million investment from the three pharmaceutical giants. In partnership with Virginia's top universities and community colleges, VCAPM aims to produce up to 2,500 highly trained professionals annually.

Academic institutions are stepping up across the board. Virginia Commonwealth University launched a Bachelor of Science in Pharmaceutical Sciences in 2024, while the Community College Workforce Alliance—a partnership between Brightpoint and Reynolds Community Colleges—offers a Pharmaceutical Manufacturing Technician certification to create multiple on-ramps into the industry. This integrated approach ensures that as new facilities come online, a skilled local workforce is ready to staff them, solidifying Virginia's role at the forefront of America's pharmaceutical resurgence.